Condition: Chronic Myeloid Leukemia, Chronic Phase · Sponsor: Korean Society of Hematology
To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
This description comes directly from the study's public registry record.
Hawk Kim · 82-10-8533-8019 · ksh.cml.wp@gmail.com
Eunju Park · 82-10-8533-8019 · ksh.cmlwp.cra1@gmail.com
Always discuss trial participation with your own doctor first.
| Gachon University Gil Medical Center | Incheon, Incheon, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06368414